Physician profile
Michael Flaherty
NPI 1821210584
$41,743.77
in general payments reported to CMS, 2019-2025
22 companies · $85.71 in 2025
The $85.71 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $12K · 2021: $836 · 2022: $16K · 2023: $933 · 2024: $375 · 2025: $85.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $38,655.22 | 2019-2024 | Impella |
| Abbott Laboratories | $879.97 | 2019-2025 | Dragonfly Opstar, Diamondback Coronary, Coroflow |
| Boston Scientific Corporation | $271.40 | 2019-2023 | Wolverine Coronary Cutting Balloon |
| Astrazeneca Pharmaceuticals Lp | $248.55 | 2020-2022 | |
| Biotronik INC. | $240.17 | 2019 | |
| Medtronic, INC. | $216.73 | 2021-2023 | Advisa Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $189.07 | 2023-2025 | |
| Terumo Medical Corporation | $186.84 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.65 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $114.95 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.95 | 2022 | |
| Amgen INC. | $82.46 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $80.66 | 2021-2023 | Eliquis, Camzyos |
| Pfizer INC. | $73.51 | 2019-2025 | |
| Cardiovascular Systems INC. | $65.11 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $48.50 | 2019 | |
| Impulse Dynamics (USA) INC. | $44.83 | 2022 | |
| Esperion Therapeutics, INC. | $33.76 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $33.12 | 2023 | Verquvo |
| Vital Connect, INC | $17.89 | 2023 | Vitalpatch Rtm |
| Novo Nordisk INC | $17.43 | 2023 | Ozempic, Rybelsus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.